All In Biotech

Drug Trial Radar · NCT06059391

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Placebo-Controlled and Randomized Phase 2 Trial of CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients After Hematopoietic Stem Cell Transplant

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 216 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

216

Planned (sponsor's estimate)

Start

Jul 9, 2024

Primary completion

Jan 1, 2027

Study completion Jan 1, 2028

Sponsor

Lead sponsor
City of Hope Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. The CMV-MVA Triplex vaccine works by causing an immune response in the donors body to the CMV virus, creating immunity to it. The donor then passes that immunity on to the patient upon receiving the stem cell transplant. Giving the CMV-MVA triplex vaccine to donors may help prevent CMV infection of patients undergoing stem cell transplantation.

Conditions

  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia, BCR-ABL1 Positive
  • Hematopoietic and Lymphoid System Neoplasm
  • Hodgkin Lymphoma
  • Myelodysplastic Syndrome
  • Myelofibrosis
  • Myeloproliferative Neoplasm
  • Non-Hodgkin Lymphoma

Interventions

  • Allogeneic Hematopoietic Stem Cell TransplantationProcedure

    Undergo HCT with donor peripheral blood stem cells

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Granulocyte Colony-Stimulating FactorDrug

    Undergo stem cell mobilization with G-CSF

  • Hematopoietic Cell Transplantation Conditioning RegimenDrug

    Receive pre transplant conditioning

  • Multi-peptide CMV-Modified Vaccinia Ankara VaccineBiological

    Given IM

  • PheresisProcedure

    Undergo apheresis

  • Placebo AdministrationDrug

    Given IM

  • Stem Cell Mobilization TherapyDrug

    Undergo stem cell mobilization with G-CSF

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from transplantation to cytomegalovirus (CMV) disease or pre-emptive treatment following CMV reactivation (efficacy)Time frame: From hematopoietic stem cell transplantation (HCT) to day 180
  2. Occurrence of non-relapse mortality (safety in HCT-recipients)Time frame: Up to day 100 post HCT
  3. Incidence of severe acute graft versus host disease (aGHVD) (safety in HCT-recipients)Time frame: Up to 100 days post HCT
  4. Incidence of severe adverse events (AEs) (safety in HCT-recipients)Time frame: Within 2 weeks from transplantation and up to 1 year post HCT
  5. Incidence of grade 3 and higher AEs (safety in HCT-donors)Time frame: Within 14 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California · Recruiting

  • Northside Hospital

    Atlanta, Georgia · Recruiting

  • DFCI/BWH Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.